| Autor: |
Gitt AK; Medical Clinic B, Department of Cardiology, Herzzentrum Ludwigshafen, Bremserstr. 79, 67117 Ludwigshafen, Germany., Laufs U; Klinik und Poliklinik für Kardiologie, University of Leipzig Medical Center, Liebigstr. 20, 04103 Leipzig, Germany., März W; Synlab Academy, 68163 Mannheim, Germany.; Medical Clinic V, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany.; Clinical Institute of Medical and Chemical Laboratory Diagnostics, University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria., Paar WD; Medical Department, Sanofi-Aventis Deutschland GmbH, Lützowstr. 107, 10785 Berlin, Germany., Bramlage P; Institute for Pharmacology and Preventive Medicine, Bahnhofstr. 20, 49661 Cloppenburg, Germany., Marx N; Clinic for Cardiology, Angiology and Intensive Medicine, University Hospital Aachen, Pauwelsstr. 30, 52074 Aachen, Germany., Parhofer KG; Medical Clinic IV-Großhadern, Ludwig Maximilian University of Munich, Marchioninistr. 15, 81377 Munich, Germany. |
| Abstrakt: |
Background: Familial hypercholesterolemia (FH) is a highly prevalent disorder and a risk factor for early coronary artery disease. The objective of this registry was to document the clinical characteristics of patients with definite FH in Germany and to document lipid profiles, lipid-lowering therapy, and lipid target achievement during longitudinal follow-up. Methods: HYDRA-FH was a national, prospective, multicenter, non-interventional registry conducted in 35 centers in Germany. Consecutive adult patients with definite FH were included (n = 241). Results: In the cross-sectional analysis (n = 233), lipid-lowering therapy involved statins (82.0%), ezetimibe (31.8%), and PCSK9 antibodies (18.5%); 11.2% of patients were receiving no lipid-lowering drugs. Median lipid levels were: low-density lipoprotein cholesterol (LDL-C) 134 mg/dL (3.5 mmol/L), high-density lipoprotein cholesterol (HDL-C) 48 mg/dL (1.2 mmol/L), triglycerides 160 mg/dL (1.9 mmol/L), total cholesterol 211 mg/dL (5.5 mmol/L). Values were above the normal threshold (150 mg/dL) for LDL-C in 72.9%, total cholesterol in 29.7%, and triglycerides in 45.0% of patients. After the 12-month follow-up (n = 145), only 17.2% had LDL-C < 70 mg/dL, and 20.7% had either LDL-C < 70 mg/dL or a reduction of ≥50% versus baseline. Conclusion: This study provides insight into the clinical characteristics and current treatment status of patients with FH in Germany. Many patients with FH do not achieve recommended lipid levels. |
